A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism

92Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

The propeptide sequences of the vitamin K-dependent clotting factors serve as a recognition site for the enzyme γ-glutamylcarboxylase, which catalyzes the carboxylation of glutamic acid residues at the NH2 terminus of the mature protein. We describe a mutation in the propeptide of Factor IX that results in warfarin sensitivity because of reduced affinity of the carboxylase for the Factor IX precursor. The proband has a Factor IX activity level of > 100% off warfarin and < 1% on warfarin, at a point where other vitamin K-dependent factors were at 30-40% activity levels. Direct sequence analysis of amplified genomic DNA from all eight exons and exon-intron junctions showed a single guanosine →adenosine transition at nucleotide 6346 resulting in an alanine to threonine change at residue -10 in the propeptide. To define the mechanism by which the mutation resulted in warfarin sensitivity, we analyzed wild-type and mutant recombinant peptides in an in vitro carboxylation reaction. The peptides that were analyzed included the wild-type sequence, the Ala-10→Thr sequence, and Ala-10→Gly, a substitution based on the sequence in bone γ-carboxyglutamic acid protein. Measurement of CO2 incorporation at a range of peptide concentrations yielded a V(max) of 343 cpm/min/reaction for the wild-type peptide, and V(max) values of 638 and 726 for A-10T and A-10G respectively, a difference of only twofold. The K(m) values, on the other hand, showed a 33-fold difference between wild-type and the variants, with a value of 0.29 μM for wild-type, and 10.9 and 9.50 μM, respectively, for A-10T and A-10G. Similar kinetic experiments showed no substantial differences between wild-type and mutant peptides in kinetic parameters of the carboxylase-peptide complexes for reduced vitamin K. We conclude that the major defect resulting from the Factor IX Ala-10→Thr mutation is a reduction in affinity of the carboxylase for the mutant propeptide. These studies delineate a novel mechanism for warfarin sensitivity. In addition, the data may also explain the observation that bone G1a protein is more sensitive to warfarin than the coagulation proteins.

Cite

CITATION STYLE

APA

Chu, K., Wu, S. M., Stanley, T., Stafford, D. W., & High, K. A. (1996). A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. Journal of Clinical Investigation, 98(7), 1619–1625. https://doi.org/10.1172/JCI118956

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free